Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYasmin AbazaSBSomedeb BallMHMichael Haddadin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows HMA-Ven treatment enhances overall survival in specific MDS patients, indicating greater benefits for those without TP53 mutation.

Key Points

  • Patients with MDS treated with HMA-Ven exhibited improved overall survival compared to HMA alone, especially in specific subgroups.
  • The analysis highlighted median overall survival of 40.6 months with HMA-Ven vs. 30 months with HMA in AHSCT patients, underlining treatment effectiveness.
  • Retrospective analysis across 19 US academic centers involved a real-world cohort of adults with varying risk levels of MDS.
  • Findings suggest HMA-Ven could be more beneficial in high-risk MDS populations, though further prospective studies are warranted.

Cite This Study

Abaza et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc64https://doi.org/10.1182/blood-2025-239
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database2025
  2. 2The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes2025
  3. 3IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  4. 4Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  5. 5Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party2025